GAN & LEE PHARMACEUTICALS. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.04 CNY | +0.89% |
|
+4.25% | -4.96% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Gan & Lee Pharmaceuticals is a China-based company mainly engaged in the research and development, production and sales of insulin analog APIs and injections. The Company's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.
Sector
Pharmaceuticals
Calendar
2024-05-16
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
50.04
CNY
Average target price
58
CNY
Spread / Average Target
+15.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.96% | 4.08B | |
| -3.79% | 87.06B | |
| +1.45% | 40.25B | |
| -16.39% | 31.09B | |
| +52.66% | 24.74B | |
| -13.91% | 15.91B | |
| -9.12% | 11.96B | |
| -15.36% | 11.92B | |
| -42.56% | 11.61B | |
| +4.87% | 8.73B |
- Stock Market
- Equities
- 603087 Stock
- News Gan & Lee Pharmaceuticals.
- Gan & Lee Pharma’s Insulin Analogs Gain EU Regulatory Approval
